right after the NDA ;-)
With a fast track designation on FDA under the GAINS act and possibly a faster NDA submission under an improved PDUFA V review process, this all could happen by this fall. Drugs such as tedizolid that are eligible for Fast Track designation are likely to be considered appropriate to receive a Priority Review. Although under the GAIN Act, as Stein has pointed out the PDUFA process has been greatly supportive if not expedited.
FDA's Fast Track Status helps expedite the regulatory process by allowing rolling submissions of data of patients enrolled in phase III clinical trials testing thus shortening the overall NDA filing and FDA decision making timelines